Stock Track | Precigen Soars 16.77% in Night Session on First Commercial Sales and Positive Earnings Report

Stock Track03-26

Precigen's stock surged 16.77% during the night session on Wednesday, following the release of the company's full-year 2025 financial results and business updates.

The biopharmaceutical company reported its first commercial sales of PAPZIMEOS, the first-and-only FDA-approved treatment for adults with recurrent respiratory papillomatosis (RRP). The drug generated $3.4 million in net product revenue in the fourth quarter of 2025, marking Precigen's transition from a clinical-stage to a commercial-stage company. Revenue for the full year reached $9.7 million, surpassing analyst expectations of $8.4 million.

Investors reacted positively to the strong commercial momentum, with management noting a significant increase in demand for PAPZIMEOS in the first quarter of 2026. Additional positive developments include the assignment of a permanent J-code for streamlined reimbursement effective April 1, 2026, and a Marketing Authorization Application under review by the European Medicines Agency. The company also stated its current cash position is expected to fund operations to cash flow break-even.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1192711163?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 09:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192711163","market":"hk","top_or_hot":-1,"title":"Stock Track | Precigen Soars 16.77% in Night Session on First Commercial Sales and Positive Earnings Report","media":"Stock Track","content":"<p>Precigen's stock surged 16.77% during the night session on Wednesday, following the release of the company's full-year 2025 financial results and business updates.</p><p>The biopharmaceutical company reported its first commercial sales of PAPZIMEOS, the first-and-only FDA-approved treatment for adults with recurrent respiratory papillomatosis (RRP). The drug generated $3.4 million in net product revenue in the fourth quarter of 2025, marking Precigen's transition from a clinical-stage to a commercial-stage company. Revenue for the full year reached $9.7 million, surpassing analyst expectations of $8.4 million.</p><p>Investors reacted positively to the strong commercial momentum, with management noting a significant increase in demand for PAPZIMEOS in the first quarter of 2026. Additional positive developments include the assignment of a permanent J-code for streamlined reimbursement effective April 1, 2026, and a Marketing Authorization Application under review by the European Medicines Agency. The company also stated its current cash position is expected to fund operations to cash flow break-even.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Precigen Soars 16.77% in Night Session on First Commercial Sales and Positive Earnings Report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Precigen Soars 16.77% in Night Session on First Commercial Sales and Positive Earnings Report\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-26 09:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Precigen's stock surged 16.77% during the night session on Wednesday, following the release of the company's full-year 2025 financial results and business updates.</p><p>The biopharmaceutical company reported its first commercial sales of PAPZIMEOS, the first-and-only FDA-approved treatment for adults with recurrent respiratory papillomatosis (RRP). The drug generated $3.4 million in net product revenue in the fourth quarter of 2025, marking Precigen's transition from a clinical-stage to a commercial-stage company. Revenue for the full year reached $9.7 million, surpassing analyst expectations of $8.4 million.</p><p>Investors reacted positively to the strong commercial momentum, with management noting a significant increase in demand for PAPZIMEOS in the first quarter of 2026. Additional positive developments include the assignment of a permanent J-code for streamlined reimbursement effective April 1, 2026, and a Marketing Authorization Application under review by the European Medicines Agency. The company also stated its current cash position is expected to fund operations to cash flow break-even.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PGEN","symbol_name":"Precigen","start_time":0,"source_url":"","article_id":"1192711163","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192711163","pubTimestamp":1774487203,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Precigen's stock surged 16.77% during the night session on Wednesday, following the release of the company's full-year 2025 financial results and business updates.The biopharmaceutical company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PGEN":"Precigen"},"translate_title":"个股追踪|Precigen夜盘飙升16.77%，首次商业销售和积极的盈利报告","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PGEN":1},"content_text":"Precigen's stock surged 16.77% during the night session on Wednesday, following the release of the company's full-year 2025 financial results and business updates.The biopharmaceutical company reported its first commercial sales of PAPZIMEOS, the first-and-only FDA-approved treatment for adults with recurrent respiratory papillomatosis (RRP). The drug generated $3.4 million in net product revenue in the fourth quarter of 2025, marking Precigen's transition from a clinical-stage to a commercial-stage company. Revenue for the full year reached $9.7 million, surpassing analyst expectations of $8.4 million.Investors reacted positively to the strong commercial momentum, with management noting a significant increase in demand for PAPZIMEOS in the first quarter of 2026. Additional positive developments include the assignment of a permanent J-code for streamlined reimbursement effective April 1, 2026, and a Marketing Authorization Application under review by the European Medicines Agency. The company also stated its current cash position is expected to fund operations to cash flow break-even.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1192711163","isCrawlerRequest":true}